Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 8:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–68 of 68 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: DNA vaccine placebo Clear all
Completed Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine

NCT02837575
View directory record Official record
Conditions
Herpes Genitalis
Interventions
VCL-HB01, Phosphate-buffered saline
Biological · Other
Lead sponsor
Vical
Industry
Eligibility
18 Years to 50 Years
Enrollment
261 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
15
States / cities
Birmingham, Alabama • San Diego, California • Hollywood, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2019 · Synced Oct 6, 2026, 8:08 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants.

NCT05683457
View directory record Official record
Conditions
Cytomegalovirus Infection
Interventions
mRNA-1647, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
3
States / cities
Boston, Massachusetts • St Louis, Missouri • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 6, 2026, 8:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Immune Response of a Prime-Boost HIV Vaccine Regimen in Healthy, HIV-Uninfected, Vaccinia-Naive Adults

NCT01571960
View directory record Official record
Conditions
HIV Infections
Interventions
GEO-D03 DNA vaccine, MVA/HIV62B (MVA62B) vaccine, Placebo for GEO-D03 DNA, Placebo for MVA62B:
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
4
States / cities
Birmingham, Alabama • San Francisco, California • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2021 · Synced Oct 6, 2026, 8:08 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults

NCT04516746
View directory record Official record
Conditions
COVID-19, SARS-CoV-2
Interventions
AZD1222, Placebo
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
32,450 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
78
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 66 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2024 · Synced Oct 6, 2026, 8:08 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects

NCT01190176
View directory record Official record
Conditions
Infections, Papillomavirus
Interventions
Gynaecological follow-up, Cervarix, Placebo control
Procedure · Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
28 Years and older · Female only
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2017
U.S. locations
3
States / cities
Iowa City, Iowa • Wichita, Kansas • Wenatchee, Washington
Source: ClinicalTrials.gov public record
Updated Oct 30, 2019 · Synced Oct 6, 2026, 8:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to an HIV-1 Vaccine Boost (VRC-HIVADV014-00-VP) in HIV Uninfected Adults Who Participated in HVTN 052

NCT00091416
View directory record Official record
Conditions
HIV Infections
Interventions
VRC-HIVADV014-00-VP
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2006
U.S. locations
8
States / cities
Baltimore, Maryland • Boston, Massachusetts • St Louis, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Oct 6, 2026, 8:08 PM EDT
Completed Phase 1 Interventional Results available

Therapeutic Vaccine for HIV

NCT01859325
View directory record Official record
Conditions
HIV, Therapeutic Vaccine
Interventions
rVSV, IL-12 pDNA adjuvant, HIV-Mag pDNA, Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2020 · Synced Oct 6, 2026, 8:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of pDNA Vaccines Expressing HIV M Group p24^Gag Conserved Elements and/or p55^Gag, Administered With IL-12 pDNA

NCT03181789
View directory record Official record
Conditions
HIV Infections
Interventions
p24CE1/2 pDNA Vaccine, p55^gag pDNA Vaccine, IL-12 pDNA Adjuvant, Placebo, Ichor Medical Systems Intramuscular TriGrid Delivery System (TDS-IM) electroporation (EP) device
Biological · Device
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
3
States / cities
San Francisco, California • Decatur, Georgia • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 7, 2024 · Synced Oct 6, 2026, 8:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to the PENNVAX-B DNA Vaccine With and Without IL-12 in HIV-uninfected Adults

NCT00991354
View directory record Official record
Conditions
HIV Infections
Interventions
PENNVAX-B, IL-12 DNA plasmids
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
3
States / cities
Rochester, New York • Philadelphia, Pennsylvania • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Oct 6, 2026, 8:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluating the Immunogenicity of the AIDSVAX B/E Vaccine and the MVA/HIV62B Vaccine in Healthy, HIV-1-Uninfected Adults Who Previously Received MVA/HIV62B in DNA/MVA or MVA/MVA Regimens in HVTN 205

NCT02852005
View directory record Official record
Conditions
HIV Infections
Interventions
MVA/HIV62B vaccine, AIDSVAX B/E vaccine, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
7
States / cities
Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2022 · Synced Oct 6, 2026, 8:08 PM EDT
Recruiting Phase 2 Interventional

PVX4 for the Treatment of Human Papilloma Virus (HPV)16+ Cervical Dysplasia

NCT07454915
View directory record Official record
Conditions
Cervical Intraepithelial Neoplasia Grade 2/3, Human Papilloma Virus Infection Type 16
Interventions
PVX4 Combination Product, Placebo Control
Combination Product · Other
Lead sponsor
PapiVax Biotech, Inc.
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 6, 2026, 8:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to a DNA HIV Vaccine (pGA2/JS7) Boosted With a Modified Vaccinia HIV Vaccine (MVA/HIV62) in Healthy Adults

NCT00301184
View directory record Official record
Conditions
HIV Infections
Interventions
pGA2/JS7 DNA, Modified vaccinia Ankara/HIV62
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
6
States / cities
Birmingham, Alabama • Baltimore, Maryland • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2022 · Synced Oct 6, 2026, 8:08 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety, Tolerability and Immune Response to LC002, an Experimental Therapeutic Vaccine, in Adults Receiving HAART

NCT00270205
View directory record Official record
Conditions
HIV Infections
Interventions
LC002 standard vaccination, LC002 high-dose vaccination, LC002 placebo vaccination
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
5
States / cities
Sacramento, California • Chicago, Illinois • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 6, 2026, 8:08 PM EDT
Not yet recruiting Phase 2 Interventional Accepts healthy volunteers

Evaluating the Safety and Immunogenicity of Polyvalent DNA and Recombinant gp120 Protein HIV Vaccine (PDPHV) in Healthy, HIV-uninfected Adults

NCT07675629
View directory record Official record
Conditions
HIV Prevention
Interventions
PDPHV Plasmid DNA Vaccines (env (A, B, C, A/E)/gag (C)), PDPHV Recombinant Protein Vaccines (gp120 (A, B, C, A/E)), Alhydrogel adjuvant, GLA-SE adjuvant, Placebo for DNA Vaccines, Protein Vaccines and Adjuvants
Biological
Lead sponsor
Worcester HIV Vaccine
Industry
Eligibility
18 Years to 55 Years
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 6, 2026, 8:08 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy Trial of DNA Vaccines to Treat Genital Herpes in Adults

NCT02030301
View directory record Official record
Conditions
Genital Herpes Simplex Type 2
Interventions
VCL-HB01, VCL-HM01, PBS
Biological
Lead sponsor
Vical
Industry
Eligibility
18 Years to 50 Years
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
7
States / cities
Birmingham, Alabama • Hollywood, Florida • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2019 · Synced Oct 6, 2026, 8:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Phase 1 Dose Escalation Study to Examine the Safety of the P2-VP8 Rotavirus Vaccine

NCT01764256
View directory record Official record
Conditions
Rotavirus Infection
Interventions
P2-VP8 subunit rotavirus vaccine, placebo
Biological · Other
Lead sponsor
PATH
Other
Eligibility
18 Years to 45 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 12, 2019 · Synced Oct 6, 2026, 8:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Immune Response to Three HIV Vaccine Schedules in Healthy, HIV-Uninfected Adults

NCT01783977
View directory record Official record
Conditions
HIV Infections
Interventions
DNA-HIV-PT123 vaccine, NYVAC-HIV-PT1 vaccine, NYVAC-HIV-PT4 vaccine, Placebo for DNA-HIV-PT123 vaccine, Placebo for NYVAC-HIV-PT1 vaccine, Placebo for NYVAC-HIV-PT4 vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
143 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
7
States / cities
Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2021 · Synced Oct 6, 2026, 8:08 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Early Immune Responses to Vaccination - A Substudy to HVTN 205

NCT00908323
View directory record Official record
Conditions
HIV Infections
Interventions
JS7 DNA vaccine, MVA/HIV62 vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
3
States / cities
Birmingham, Alabama • San Francisco, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 15, 2021 · Synced Oct 6, 2026, 8:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety and Immunogenicity Phase IC Study of CryJ2 -DNA-LAMP Plasmid Vaccine for Assessment of Intradermal (ID) Route of Administration Using the Biojector 2000 Device

NCT02146781
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
CryJ2-DNA-LAMP plasmid vaccine by intradermal injection, Saline Control
Biological · Other
Lead sponsor
Immunomic Therapeutics, Inc.
Industry
Eligibility
18 Years to 63 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Mar 25, 2015 · Synced Oct 6, 2026, 8:08 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647 in Healthy Adults

NCT04232280
View directory record Official record
Conditions
Cytomegalovirus Infection
Interventions
mRNA-1647, Placebo
Biological · Other
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years to 40 Years
Enrollment
315 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
9
States / cities
Sacramento, California • Peoria, Illinois • Lenexa, Kansas + 5 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 6, 2026, 8:08 PM EDT